Study · Randomized controlled trial · 2001

12 results

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH

The New England journal of medicine1 May 2001Cited by 3,051 (Europe PMC)

PMID11346808DOI10.1056/nejm200105103441904PepBankPUB-11346808

Source link PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, PTH reduced new vertebral fractures versus placebo.
In plain wordsPTH reduced new vertebral fractures compared with placebo in postmenopausal women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNew vertebral fractures
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
Fractures
5 percent
20-microg group
Fractures
14 percent
placebo
Relative risk
0.35 ratio
versus placebo
Source sentences
Summary
New vertebral fractures occurred in 14 percent of the women in the placebo group and in 5 percent and 4 percent, respectively, of the women in the 20-microg and 40-microg parathyroid hormone groups; the respective relative risks of fracture in the 20-microg and 40-microg groups, as compared with the…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680801
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, PTH reduced new vertebral fractures versus placebo.
In plain wordsPTH reduced new vertebral fractures compared with placebo in postmenopausal women with osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNew vertebral fractures
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
Fractures
4 percent
40-microg group
Fractures
14 percent
placebo
Relative risk
0.31 ratio
40-microg versus placebo
Source sentences
Summary
New vertebral fractures occurred in 14 percent of the women in the placebo group and in 5 percent and 4 percent, respectively, of the women in the 20-microg and 40-microg parathyroid hormone groups; the respective relative risks of fracture in the 20-microg and 40-microg groups, as compared with the…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680802
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH reduced nonvertebral fragility fractures versus placebo.
In plain wordsPTH reduced nonvertebral fragility fractures compared with placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
Fractures
3 percent
20-microg group
Fractures
6 percent
placebo
Relative risk
0.47 ratio
20-microg versus placebo
Source sentences
Summary
New nonvertebral fragility fractures occurred in 6 percent of the women in the placebo group and in 3 percent of those in each parathyroid hormone group (relative risk, 0.47 and 0.46, respectively [95 percent confidence intervals, 0.25 to 0.88 and 0.25 to 0.861).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680803
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH reduced nonvertebral fragility fractures versus placebo.
In plain wordsPTH reduced nonvertebral fragility fractures compared with placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
Fractures
3 percent
40-microg group
Fractures
6 percent
placebo
Relative risk
0.46 ratio
40-microg versus placebo
Source sentences
Summary
New nonvertebral fragility fractures occurred in 6 percent of the women in the placebo group and in 3 percent of those in each parathyroid hormone group (relative risk, 0.47 and 0.46, respectively [95 percent confidence intervals, 0.25 to 0.88 and 0.25 to 0.861).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680804
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH increased lumbar spine bone mineral density more than placebo.
In plain wordsPTH increased lumbar spine bone density more than placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine bone mineral density
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
BMD difference
9 percentage points
20-microg versus placebo
Source sentences
Summary
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the ra…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680805
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH increased lumbar spine bone mineral density more than placebo.
In plain wordsPTH increased lumbar spine bone density more than placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine bone mineral density
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
BMD difference
13 percentage points
40-microg versus placebo
Source sentences
Summary
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the ra…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680806
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH increased femoral neck bone mineral density more than placebo.
In plain wordsPTH increased femoral neck bone density more than placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck bone mineral density
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
BMD difference
3 percentage points
20-microg versus placebo
Source sentences
Summary
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the ra…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680807
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH increased femoral neck bone mineral density more than placebo.
In plain wordsPTH increased femoral neck bone density more than placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck bone mineral density
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
BMD difference
6 percentage points
40-microg versus placebo
Source sentences
Summary
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the ra…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680808
09HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, PTH decreased radial shaft bone mineral density more than placebo.
In plain wordsPTH decreased radial shaft bone density more than placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadial shaft bone mineral density
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
BMD decrease difference
2 percentage points
40-microg versus placebo
Source sentences
Summary
As compared with placebo, the 20-microg and 40-microg doses of parathyroid hormone increased bone mineral density by 9 and 13 more percentage points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the ra…
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680809
10HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, both PTH doses increased total-body bone mineral more than placebo.
In plain wordsBoth PTH doses increased total-body bone mineral more than placebo in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal-body bone mineral
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Measurements
Bone mineral difference
2 to 4 percentage points
PTH versus placebo
Source sentences
Summary
Both doses increased total-body bone mineral by 2 to 4 more percentage points than did placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680810
11HumanRandomized controlled trialSafety outcome
In postmenopausal women, occasional nausea was reported with PTH treatment.
In plain wordsWomen treated with PTH reported occasional nausea.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 or 40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Source sentences
Summary
Parathyroid hormone had only minor side effects (occasional nausea and headache).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680811
12HumanRandomized controlled trialSafety outcome
In postmenopausal women, occasional headache was reported with PTH treatment.
In plain wordsWomen treated with PTH reported occasional headache.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHeadache
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
20 or 40 microg · subcutaneous daily · Median observation 21 monthsAs given in this study (human).
Source sentences
Summary
Parathyroid hormone had only minor side effects (occasional nausea and headache).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. We obtained vertebral radiographs at base line and at the end of the study (median duration of observatio…
Report a problemFND-1134680812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 1 not yet recruiting · 3 completed · 2 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 1/2NCT06303284

PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)

University of Calgaryn = 54est. 15 Mar 2027 to est. 17 Mar 2031

Lower Extremity Fractures · Pelvis · Acetabulum

Trial page ClinicalTrials.govUpdated 6 Oct 2026

CompletedNot applicableNCT02563353

PTH and Vibration in OSteoporosis Study

Odense University Hospitaln = 35Nov 2015 to Nov 2019

Osteoporosis

Trial page ClinicalTrials.govUpdated 18 Sept 2020

WithdrawnPhase 1NCT01333267

One Week Comparison Study of PTH and PTHrP Infusions

University of Pittsburghn = 0Jan 2015 to est. Jul 2017

Osteoporosis · Hypercalcemia of Malignancy · Hyperparathyroidism · Bone Diseases, Endocrine

Trial page ClinicalTrials.govUpdated 5 Dec 2014

TerminatedPhase 2Results postedNCT01279187

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

University of Michigann = 27Feb 2011 to Nov 2015

Implant

Trial page ClinicalTrials.govUpdated 7 Feb 2018

CompletedPhase 2Results postedNCT00926380

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Massachusetts General Hospitaln = 94Jun 2009 to Dec 2016

Osteoporosis

Trial page ClinicalTrials.govUpdated 29 Jun 2018

CompletedPhase 2Results postedNCT00853723

Comparison Study of PTHrP and PTH to Treat Osteoporosis

University of Pittsburghn = 105May 2009 to Jun 2012

Osteoporosis

Trial page ClinicalTrials.govUpdated 24 Mar 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.